# Avutometinib and Defactinib in Diffuse Gastric Cancer

> **NCT06487221** · PHASE2 · RECRUITING · sponsor: **Ryan H. Moy, MD, PhD** · enrollment: 27 (estimated)

## Conditions studied

- Gastric Cancer
- Stomach Cancer

## Interventions

- **DRUG:** Avutometinib
- **DRUG:** Defactinib

## Key facts

- **NCT ID:** NCT06487221
- **Lead sponsor:** Ryan H. Moy, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-28
- **Primary completion:** 2028-11-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06487221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06487221, "Avutometinib and Defactinib in Diffuse Gastric Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06487221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*